Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:60058 |
Name | lymphoma |
Definition | A hematologic cancer that affects lymphocytes that reside in the lymphatic system and in blood-forming organs. |
Source | DiseaseOntology.org |
Alt Ids | DOID:353 DOID:1033 |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
NRAS mutant | Trametinib | lymphoma | sensitive | detail... |
TP53 wild-type | ALRN-6924 | lymphoma | predicted - sensitive | detail... |
ALK negative | CEP-28122 | lymphoma | resistant | detail... |
BRAF mutant | Trametinib | lymphoma | no benefit | detail... |
MAP2K1 F53C | Vemurafenib | lymphoma | predicted - resistant | detail... |
ALK rearrange | Crizotinib | lymphoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00084695 | Phase II | Fludarabine Busulfan + Melphalan anti-thymocyte globulin Cyclophosphamide Prednisone | Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases | Unknown status | USA | 0 |
NCT00368082 | Phase I | Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta) (TGF-beta) | Active, not recruiting | USA | 0 | |
NCT00585195 | Phase I | Crizotinib + Itraconazole Crizotinib + Rifampin | A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer (PROFILE 1001) | Completed | USA | AUS | 2 |
NCT00608361 | Phase I | Dasatinib | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery | Completed | USA | 0 |
NCT00918333 | Phase Ib/II | Everolimus + Panobinostat | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | Completed | USA | 0 |
NCT01237236 | Phase I | Ribociclib | A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma. | Completed | USA | NLD | FRA | 0 |
NCT01273155 | Phase I | Belinostat | Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction | Completed | USA | 0 |
NCT01287546 | Phase I | Emibetuzumab + Erlotinib Emibetuzumab + Trametinib Emibetuzumab | A Study of LY2875358 in Participants With Advanced Cancer | Completed | USA | 0 |
NCT01326702 | Phase Ib/II | Veliparib Rituximab Bendamustine | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | Completed | USA | 0 |
NCT01327612 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Ganitumab Bevacizumab Conatumumab | Open Label Extension Study of Conatumumab and AMG 479 | Completed | USA | POL | ESP | 0 |
NCT01363817 | Phase I | Dexamethasone BMS-906024 | Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma | Completed | USA | FRA | DEU | 0 |
NCT01393509 | Phase I | PU-H71 | The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies | Completed | USA | 0 |
NCT01473095 | Phase I | Miransertib | Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma | Completed | USA | 0 |
NCT01498484 | Phase II | EB-VST cells | Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies | Completed | USA | 0 |
NCT01564251 | Phase I | GDC-0575 + Gemcitabine GDC-0575 | A Study of GDC-0575 Alone And in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma | Completed | USA | FRA | 0 |
NCT01576406 | Phase I | Crizotinib | Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients | Completed | USA | 0 |
NCT01596270 | Phase I | Voxtalisib | A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma | Completed | USA | 0 |
NCT01625351 | Phase I | Fludarabine Melphalan Busulfan Alemtuzumab | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | Completed | USA | 0 |
NCT01636479 | Phase I | SAR405838 | Phase 1 Safety Testing of SAR405838 | Completed | USA | NLD | FRA | 0 |
NCT01638533 | Phase I | Romidepsin | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | Active, not recruiting | USA | CAN | 0 |
NCT01655225 | Phase I | LY3023414 + Midazolam Letrozole + LY3023414 LY3023414 | A Study of LY3023414 in Participants With Advanced Cancer | Completed | USA | ITA | 1 |
NCT01665768 | Phase II | Rituximab Everolimus | Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma | Completed | USA | 0 |
NCT01670175 | Phase I | Cyclophosphamide + Sirolimus + Topotecan | Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors | Completed | USA | 0 |
NCT01673737 | Phase I | SAR260301 SAR260301 + Vemurafenib | A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer | Completed | USA | CAN | 0 |
NCT01695005 | Phase I | LY3039478 | A Study of LY3039478 in Participants With Advanced Cancer | Completed | USA | GBR | FRA | ESP | DNK | DEU | 0 |
NCT01703481 | Phase I | Erdafitinib | A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Patients With Advanced or Refractory Solid Tumors or Lymphoma | Completed | USA | FRA | ESP | 0 |
NCT01703572 | Phase I | Brontictuzumab | A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies | Completed | USA | 0 |
NCT01703949 | Phase II | Brentuximab vedotin Brentuximab vedotin + Nivolumab | Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma | Recruiting | USA | 0 |
NCT01744223 | Phase Ib/II | Rimiducid Rivogenlecleucel | Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant | Active, not recruiting | USA | 0 |
NCT01744652 | Phase I | Crizotinib + Dasatinib | Dasatinib and Crizotinib in Advanced Cancer | Completed | USA | 0 |
NCT01829971 | Phase I | MRX34 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | Terminated | USA | 1 |
NCT01844583 | Phase I | Alisertib + Esomeprazole Alisertib + Rifampin Alisertib | Safety, Tolerability and PK of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib | Completed | USA | 0 |
NCT01877382 | Phase I | Milademetan | A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral Murine Double Minute 2 (MDM2) Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas | Completed | USA | 0 |
NCT01885897 | Phase Ib/II | Nogapendekin alfa inbakicept | IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT | Completed | USA | 0 |
NCT01897012 | Phase I | Romidepsin Alisertib | Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas | Completed | USA | 0 |
NCT01898078 | Phase I | Alisertib | Food Effect Study of Alisertib (MLN8237) in Patients With Advanced Solid Tumors or Lymphomas | Completed | USA | 0 |
NCT01905228 | Phase I | CBL0137 | A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm or Refractory Lymphomas | Completed | USA | 0 |
NCT01908413 | Phase I | GDC-0917 | Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma | Terminated | USA | 0 |
NCT01919619 | Phase II | Ipilimumab + Lenalidomide | Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies | Completed | USA | 0 |
NCT01943682 | Phase I | CPX-351 | Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma | Completed | USA | 0 |
NCT01947140 | Phase Ib/II | Pralatrexate + Romidepsin | Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies (PDX+Romi) | Completed | USA | 0 |
NCT01991938 | Phase I | VS-5584 | Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma | Terminated | USA | GBR | 0 |
NCT01992653 | Phase I | Cyclophosphamide + Doxorubicin + Prednisone Rituximab Polatuzumab vedotin-piiq Obinutuzumab | A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma | Completed | USA | FRA | 0 |
NCT01998035 | Phase Ib/II | Azacitidine + Romidepsin | Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies | Terminated | USA | 0 |
NCT02042989 | Phase I | Ixazomib + Vorinostat | MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies | Completed | USA | 0 |
NCT02203903 | Phase I | MultiTAA-specific T cells | Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies (RESOLVE) | Recruiting | USA | 0 |
NCT02216409 | Phase I | Hu5F9-G4 | Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody | Completed | USA | 0 |
NCT02249429 | Phase Ib/II | PQR309 | Open-Label, Non Randomized Phase 2 Study With Safety Run-In | Completed | USA | ISR | GBR | FRA | 2 |
NCT02259010 | Phase I | Alisertib Itraconazole | A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma | Completed | USA | 0 |
NCT02287311 | Phase I | LMP/BARF1/EBNA1-specific cytotoxic T lymphocytes Cyclophosphamide + Fludarabine | Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) | Recruiting | USA | 0 |
NCT02309580 | Phase I | Ibrutinib | Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma | Completed | USA | 0 |
NCT02318329 | Phase I | Bemarituzumab | Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors | Completed | USA | 2 |
NCT02323880 | Phase I | Selinexor | Study of Selinexor in Pediatric Solid Tumors | Active, not recruiting | USA | 0 |
NCT02332668 | Phase Ib/II | Pembrolizumab | A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | Recruiting | USA | SWE | NLD | ITA | ISR | GBR | FRA | DEU | BRA | 1 |
NCT02337985 | Phase I | Rituximab Cyclophosphamide + Doxorubicin + Etoposide + Vincristine Sulfate Filgrastim Prednisone | Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT02343718 | Phase I | Temsirolimus + Vinblastine | Vinblastine and Temsirolimus in Pediatric Patients With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours | Completed | CAN | 0 |
NCT02355535 | Phase I | PAC-1 | Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies | Completed | USA | 0 |
NCT02356159 | Phase Ib/II | Cytarabine + Fludarabine Palifermin Prednisone Filgrastim Methotrexate + Sirolimus + Tacrolimus Doxorubicin + Etoposide + Fludarabine + Vincristine Sulfate Cyclophosphamide + Fludarabine Rituximab | Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation | Active, not recruiting | USA | 0 |
NCT02376699 | Phase I | Pembrolizumab + SEA-CD40 SEA-CD40 | Safety Study of SEA-CD40 in Cancer Patients | Terminated | USA | 0 |
NCT02392611 | Phase I | Exemestane + GS-5829 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 in Adults With Advanced Solid Tumors and Lymphomas | Completed | USA | 0 |
NCT02414724 | Phase I | Gemcitabine + Ribociclib | Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma | Terminated | USA | 0 |
NCT02431260 | Phase I | INCB054329 | An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies | Terminated | USA | 0 |
NCT02432235 | Phase I | Camidanlumab tesirine | Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma | Completed | USA | GBR | 0 |
NCT02440685 | Phase Ib/II | ASN002 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | Terminated | USA | ARG | 0 |
NCT02465060 | Phase II | Nivolumab + Relatlimab Dabrafenib + Trametinib | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | Active, not recruiting | USA | 2 |
NCT02477878 | Phase I | BPX-601 Rimiducid | Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant | Active, not recruiting | USA | 0 |
NCT02499861 | Phase Ib/II | Decitabine + Genistein | Phase I/II a Study of Decitabine in Combination With Genistein in Pediatric Relapsed or Refractory Malignancies | Completed | CAN | 0 |
NCT02503423 | Phase Ib/II | ASTX-660 | Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas | Active, not recruiting | USA | ITA | HUN | GBR | FRA | ESP | CAN | BEL | 0 |
NCT02516813 | Phase I | Peposertib | Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy | Completed | USA | SWE | NOR | NLD | DNK | DEU | CHE | BEL | 0 |
NCT02518113 | Phase Ib/II | Dexamethasone LY3039478 | A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL | Completed | USA | ITA | ISR | FRA | DEU | 0 |
NCT02518750 | Phase II | Bortezomib + Dexamethasone + Panobinostat Pegaspargase Mercaptopurine Nelarabine Mitoxantrone Vincristine Sulfate Cyclophosphamide + Etoposide Cytarabine + Methotrexate + Prednisone Clofarabine | Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma | Terminated | USA | 0 |
NCT02518958 | Phase I | Nivolumab | A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab | Completed | USA | 0 |
NCT02538926 | Phase II | Imatinib Rituximab Cyclophosphamide Prednisone Doxorubicin + Etoposide + Vincristine Sulfate Asparaginase | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | Withdrawn | USA | 0 |
NCT02552953 | Phase I | CYC065 | A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers | Completed | USA | 0 |
NCT02575638 | Phase I | CZ48 | Safety Study of Camptothecin-20-O-Propionate Hydrate (CZ48) | Unknown status | USA | 0 |
NCT02582827 | Phase I | ABI-011 | QUILT-3.014: A Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas | Withdrawn | USA | 0 |
NCT02624388 | Phase II | Genistein | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) | Terminated | USA | 0 |
NCT02661542 | Phase Ib/II | FF-10502 | Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas | Completed | USA | 0 |
NCT02663518 | Phase I | TTI-621 | A Trial of TTI-621 for Patients With Hematologic Malignancies | Terminated | USA | CAN | 0 |
NCT02675439 | Phase I | Ipilimumab + MIW815 MIW815 | Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas | Terminated | USA | 0 |
NCT02681302 | Phase Ib/II | Ipilimumab + Nivolumab | Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence (CPIT001) | Terminated | USA | 0 |
NCT02683395 | Phase I | PLX51107 | A Study of PLX51107 in Advanced Malignancies | Terminated | USA | 0 |
NCT02694822 | Phase I | Zalifrelimab | AGEN-1884, an Anti-CTLA-4 Antibody, in Advanced Solid Cancers | Completed | USA | 0 |
NCT02729896 | Phase Ib/II | Obinutuzumab + Polatuzumab vedotin-piiq + Rituximab Atezolizumab + Obinutuzumab + Polatuzumab vedotin-piiq | A Study of Obinutuzumab, Polatuzumab Vedotin, and Atezolizumab in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) | Completed | USA | POL | DEU | 0 |
NCT02740270 | Phase I | GWN 323 + Spartalizumab GWN 323 | Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas | Completed | USA | ISR | ESP | CAN | 2 |
NCT02780011 | Phase I | Alisertib + Brentuximab vedotin | Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies | Withdrawn | USA | 0 |
NCT02780804 | Phase I | Entinostat | Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors | Completed | USA | 0 |
NCT02783625 | Phase I | Bortezomib + Duvelisib Duvelisib + Romidepsin | Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas | Active, not recruiting | USA | 0 |
NCT02784795 | Phase I | Cisplatin + Gemcitabine + LY3039478 Carboplatin + Gemcitabine + LY3039478 LY3023414 + LY3039478 Abemaciclib + LY3039478 LY3039478 + Taladegib LY3039478 LY3023414 | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors | Completed | USA | FRA | ESP | DNK | 0 |
NCT02786485 | Phase I | Rimiducid Rivogenlecleucel | Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT | Withdrawn | 0 | |
NCT02793466 | Phase I | Durvalumab | Durvalumab in Pediatric and Adolescent Patients | Completed | USA | 0 |
NCT02793544 | Phase II | Cyclophosphamide Busulfan Sirolimus Mycophenolate mofetil Mesna Fludarabine | HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide | Completed | USA | 0 |
NCT02812875 | Phase I | CA-170 | A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas | Completed | USA | GBR | ESP | 1 |
NCT02846935 | Phase 0 | Decitabine + Tetrahydrouridine | p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies | Completed | USA | 0 |
NCT02875548 | Phase II | Tazemetostat | Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study | Enrolling by invitation | USA | POL | GBR | FRA | BEL | AUS | 1 |
NCT02909777 | Phase I | CUDC-907 | Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma | Active, not recruiting | USA | 0 |
NCT02911142 | Phase Ib/II | Cyclophosphamide + Doxorubicin + Etoposide + Lenalidomide + Prednisone + Rituximab + Vincristine Sulfate | Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT02922764 | Phase I | RGX-104 Ipilimumab + RGX-104 Nivolumab + RGX-104 Carboplatin + Pembrolizumab + Pemetrexed Disodium + RGX-104 | A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma | Active, not recruiting | USA | 0 |
NCT02932280 | Phase Ib/II | Neratinib | Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment | Active, not recruiting | USA | CAN | 0 |
NCT02935907 | Phase I | Alrizomadlin | APG-115 in Patients With Advanced Solid Tumors or Lymphomas | Completed | USA | 0 |
NCT02992483 | Phase I | MIK665 | Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma | Completed | USA | ITA | FRA | ESP | DEU | AUS | 1 |
NCT03005782 | Phase I | Cemiplimab + Fianlimab Fianlimab | Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers | Completed | USA | IRL | GBR | AUS | 1 |
NCT03010176 | Phase I | Pembrolizumab + Ulevostinag Ulevostinag | Study of MK-1454 Alone or in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001) | Completed | USA | ISR | GBR | FRA | 1 |
NCT03013218 | Phase I | Evorpacept Atezolizumab + Evorpacept Evorpacept + Trastuzumab | A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma | Active, not recruiting | USA | 1 |
NCT03013491 | Phase II | CX-072 + Ipilimumab CX-072 + Vemurafenib CX-072 | A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas | Completed | USA | POL | NLD | GBR | ESP | 1 |
NCT03017820 | Phase I | VSV-hIFNbeta-NIS | VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma | Recruiting | USA | 0 |
NCT03030417 | Phase I | LMP744 | Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas | Completed | USA | 0 |
NCT03061188 | Phase I | Nivolumab + Veliparib | Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes | Completed | USA | 0 |
NCT03155620 | Phase II | Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | Recruiting | USA | CAN | AUS | 1 |
NCT03162536 | Phase I | ARQ 531 | Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT03172936 | Phase I | MIW815 + Spartalizumab | Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas | Terminated | USA | NLD | ESP | DEU | CHE | CAN | AUS | 1 |
NCT03192202 | Phase Ib/II | AFM13 | AFM13 in Relapsed/Refractory Cutaneous Lymphomas | Completed | USA | 0 |
NCT03194893 | Phase III | Crizotinib Alectinib | A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer | Recruiting | USA | TUR | POL | ITA | FRA | ESP | 4 |
NCT03199586 | Phase I | NP-G2-044 | Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) | Completed | USA | 0 |
NCT03205176 | Phase I | AZD5153 | Phase I Study of AZD5153 in Patients With Relapsed or Refractory Solid Tumors and Lymphomas | Completed | USA | CAN | 0 |
NCT03229200 | FDA approved | Ibrutinib | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | Enrolling by invitation | USA | TUR | SWE | POL | NZL | ITA | HUN | GBR | FRA | ESP | CZE | CAN | AUS | 4 |
NCT03229278 | Phase I | Nivolumab + Pembrolizumab + Trigriluzole | Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | Completed | USA | 0 |
NCT03241940 | Phase I | Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells | Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies | Recruiting | USA | 0 |
NCT03249792 | Phase I | MK-2118 + Pembrolizumab MK-2118 | Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) in the Treatment of Adults With Advance/Metastatic Solid Tumors or Lymphomas (MK-2118-001) | Terminated | USA | ISR | 0 |
NCT03259503 | Phase Ib/II | Busulfan Olaparib Vorinostat Palifermin Gemcitabine Melphalan Dexamethasone Pyridoxine Rituximab | Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas | Active, not recruiting | USA | 0 |
NCT03291938 | Phase I | IACS-010759 | Study to Evaluate the Safety and Tolerability of IACS-010759 in Subjects With Advanced Solid Tumors and Lymphoma | Completed | USA | 0 |
NCT03309878 | Phase Ib/II | Pembrolizumab Mogamulizumab + Pembrolizumab | Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Lymphomas | Completed | USA | 0 |
NCT03311412 | Phase I | Sym021 | Sym021 (Anti-PD-1) in Patients With Advanced Solid Tumor Malignancies or Lymphomas | Completed | USA | CAN | 0 |
NCT03316573 | Phase II | Pembrolizumab | A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas | Suspended | USA | 0 |
NCT03322384 | Phase Ib/II | Epacadostat + SD-101 | Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma | Completed | USA | 0 |
NCT03323034 | Phase I | Irinotecan + MLN4924 + Temozolomide | Pevonedistat, Irinotecan Hydrochloride, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma | Completed | USA | 0 |
NCT03323398 | Phase I | mRNA-2416 | Dose Escalation Study of mRNA 2416 for Intratumoral Injection to Patients With Advanced Malignancies | Terminated | USA | 0 |
NCT03332355 | Phase I | PAC-1 + Temozolomide | Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2 | Terminated | USA | 0 |
NCT03359733 | Phase I | Mivavotinib | A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor | Withdrawn | USA | 0 |
NCT03365791 | Phase II | Ieramilimab Spartalizumab | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | Completed | USA | 0 |
NCT03418038 | Phase II | Dexamethasone Carboplatin + Etoposide + Ifosfamide Carboplatin + Etoposide + Ifosfamide + Rituximab Cisplatin + Cytarabine + Dexamethasone Cisplatin + Dexamethasone + Gemcitabine Rituximab Cytarabine + Dexamethasone + Oxaliplatin Gemcitabine + Oxaliplatin Cisplatin + Cytarabine + Dexamethasone + Rituximab | Ascorbic Acid and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma | Recruiting | USA | 0 |
NCT03435250 | Phase I | AG-270 + Docetaxel AG-270 + Gemcitabine + Nab-paclitaxel AG-270 | Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss | Terminated | USA | FRA | ESP | 0 |
NCT03445858 | Phase I | Decitabine + Pembrolizumab | Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults | Completed | USA | 0 |
NCT03448393 | Phase I | Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | Recruiting | USA | 0 |
NCT03451825 | Phase Ib/II | Avelumab | Phase I/II Study of Avelumab in Pediatric Cancer Subjects | Terminated | USA | DNK | CAN | BEL | 1 |
NCT03458728 | Phase Ib/II | Copanlisib | Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients | Terminated | USA | 0 |
NCT03478462 | Phase I | CLR 131 | Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Brain Cancer, Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma | Active, not recruiting | USA | CAN | AUS | 0 |
NCT03489343 | Phase I | Sym023 | Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas | Completed | USA | CAN | 0 |
NCT03489369 | Phase I | Sym022 | Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas | Completed | USA | CAN | 0 |
NCT03502733 | Phase I | Copanlisib + Nivolumab | Copanlisib and Nivolumab in Treating Patients With Metastatic Solid Tumors or Lymphoma | Active, not recruiting | USA | 0 |
NCT03505554 | Phase II | Lorlatinib | A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma (CRU3) | Recruiting | ITA | 0 |
NCT03530683 | Phase I | TTI-622 | A Trial of TTI-622 in Patients With Advanced Relapsed or Refractory Lymphoma or Myeloma | Terminated | USA | 0 |
NCT03556228 | Phase I | VMD-928 | Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | Recruiting | USA | 1 |
NCT03648372 | Phase I | Subasumstat | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Metastatic Solid Tumors or Lymphomas | Terminated | USA | 0 |
NCT03654716 | Phase I | ALRN-6924 + Cytarabine ALRN-6924 | Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer | Completed | USA | 0 |
NCT03674567 | Phase Ib/II | FLX475 + Pembrolizumab FLX475 | Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab | Active, not recruiting | USA | AUS | 4 |
NCT03739931 | Phase I | mRNA-2752 mRNA-2752 + Tremelimumab Durvalumab + mRNA-2752 | Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Patients With Advanced Malignancies | Active, not recruiting | USA | ISR | AUS | 0 |
NCT03763149 | Phase I | IBI188 | A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas | Completed | USA | 0 |
NCT03770000 | Phase Ib/II | Romidepsin + Tenalisib | Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma | Completed | USA | 0 |
NCT03775525 | Phase I | Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or Lymphoma (GEN602) | Active, not recruiting | USA | 0 | |
NCT03779113 | Phase Ib/II | HMPL-523 | An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma | Active, not recruiting | USA | POL | ITA | FRA | FIN | ESP | DNK | 0 |
NCT03815682 | Phase I | Pembrolizumab + RPTR-147 RPTR-147 | RPTR-147 in Patients With Selected Solid Tumors and Lymphomas | Terminated | USA | 0 |
NCT03841110 | Phase I | FT500 + Pembrolizumab Atezolizumab + FT500 FT500 + Nivolumab FT500 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | Completed | USA | 0 |
NCT03856216 | Phase II | Methotrexate Filgrastim + Methotrexate + Rituximab Rituximab Bendamustine + Fludarabine + Inotuzumab ozogamicin + Tacrolimus Filgrastim + Methotrexate Inotuzumab ozogamicin Fludarabine + Inotuzumab ozogamicin + Melphalan + Tacrolimus anti-thymocyte globulin | Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation | Recruiting | USA | 0 |
NCT03871348 | Phase I | SAR441000 Cemiplimab + SAR441000 | A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Terminated | USA | NLD | FRA | ESP | DEU | BEL | 0 |
NCT03884556 | Phase I | Gemcitabine + Nab-paclitaxel + TTX-030 Docetaxel + TTX-030 Pembrolizumab + TTX-030 TTX-030 | TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers | Completed | USA | 0 |
NCT03934372 | Phase Ib/II | Ponatinib | Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors | Recruiting | SWE | NLD | ITA | GBR | FRA | ESP | DNK | DEU | BEL | 0 |
NCT03934814 | Phase I | Lemzoparlimab Lemzoparlimab + Pembrolizumab Lemzoparlimab + Rituximab | Study of TJ011133 Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma | Completed | USA | 1 |
NCT03936465 | Phase I | BMS986158 CC-90010 | Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer | Completed | USA | CAN | 0 |
NCT04053673 | Phase I | RBN-2397 | RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors , FIH, MAD Study | Unknown status | USA | ESP | 0 |
NCT04111107 | Phase II | Precision Medicine for Patients With Identified Actionable Mutations | Terminated | USA | 0 | |
NCT04130516 | Phase Ib/II | LNS8801 LNS8801 + Pembrolizumab | Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab | Recruiting | USA | 0 |
NCT04137900 | Phase I | Icatolimab | Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies | Recruiting | USA | 0 |
NCT04138875 | Phase II | Bendamustine + Brentuximab vedotin + Rituximab Brentuximab vedotin + Rituximab | A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB) | Withdrawn | USA | 0 |
NCT04144140 | Phase I | E7766 | Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101 | Terminated | USA | GBR | FRA | ESP | 1 |
NCT04167137 | Phase I | SYNB1891 Atezolizumab + SYNB1891 | Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Subjects | Terminated | USA | 0 |
NCT04186637 | Phase I | ALPN-202 | An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies (NEON-1) | Terminated | USA | AUS | 0 |
NCT04189445 | Phase II | Futibatinib | Futibatinib in Patients With Specific FGFR Aberrations | Active, not recruiting | USA | TUR | SWE | NLD | ITA | GBR | FRA | ESP | DEU | BEL | 5 |
NCT04189952 | Phase II | Acalabrutinib + Carboplatin + Etoposide + Ifosfamide + Rituximab | Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma | Terminated | USA | 0 |
NCT04195555 | Phase II | Ivosidenib | Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | AUS | 1 |
NCT04214093 | Phase I | AZD0466 | A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors | Terminated | USA | 0 |
NCT04243499 | Phase I | ICT01 | First-in-Human Study of ICT01 in Patients With Advanced Cancer (EVICTION) | Recruiting | USA | GBR | FRA | ESP | DEU | BEL | 0 |
NCT04254107 | Phase I | SGN-TGT Pembrolizumab + SGN-TGT | A Safety Study of SGN-TGT in Patients With Advanced Cancer | Terminated | USA | ITA | GBR | FRA | ESP | CAN | 0 |
NCT04257617 | Phase I | ZL1201 | A Trial of ZL-1201 in Subjects With Advanced Cancer | Completed | USA | 1 |
NCT04261439 | Phase I | NIZ985 NIZ985 + Spartalizumab | A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab | Terminated | USA | ITA | ESP | DEU | BEL | 2 |
NCT04283097 | Phase I | KPG-818 | Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects | Recruiting | USA | 0 |
NCT04284774 | Phase II | Tipifarnib | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | Active, not recruiting | USA | 1 |
NCT04285268 | Phase II | Bortezomib + Rituximab + Venetoclax | Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Withdrawn | USA | 0 |
NCT04306224 | Phase I | IMC-002 | A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas | Completed | USA | 1 |
NCT04464798 | Phase I | Iberdomide Iberdomide + Obinutuzumab Iberdomide + Rituximab | A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas | Active, not recruiting | USA | ITA | FRA | DEU | 2 |
NCT04500548 | Phase I | Nivolumab Ipilimumab + Nivolumab | Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study | Withdrawn | USA | CAN | 0 |
NCT04571138 | Phase Ib/II | SCRI-CAR22v2 | A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma | Recruiting | USA | 0 |
NCT04588922 | Phase I | GFH009 | A Study of GFH009 in Patients With Hematologic Malignancies | Recruiting | USA | 1 |
NCT04609579 | Phase I | SNX281 Pembrolizumab + SNX281 | Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma | Terminated | USA | 0 |
NCT04639843 | Phase I | Azacitidine + Doxorubicin + Duvelisib + Romidepsin | Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma | Withdrawn | USA | 0 |
NCT04870944 | Phase Ib/II | CBL0137 | CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma | Recruiting | USA | AUS | 0 |
NCT04925544 | Phase II | VK-2019 | Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV) Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV) Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies | Recruiting | USA | 0 |
NCT04970992 | Phase I | DZ-002 | A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma | Recruiting | USA | 0 |
NCT05011058 | Phase II | CHR-3996 CHR-3996 + Valganciclovir | An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1) | Recruiting | USA | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BRA | AUS | 5 |
NCT05020678 | Phase I | Cyclophosphamide + Fludarabine NKX019 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | Recruiting | USA | AUS | 0 |
NCT05053971 | Phase Ib/II | Entinostat + ZEN-3694 | Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas | Recruiting | USA | 0 |
NCT05065866 | Phase I | Azacitidine + Duvelisib | Duvelisib in Combination With CC-486 in Lymphoid Malignancy | Active, not recruiting | USA | 0 |
NCT05071209 | Phase Ib/II | Elimusertib | Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors | Active, not recruiting | USA | CAN | 0 |
NCT05093322 | Phase Ib/II | Gemcitabine + Surufatinib | A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors | Completed | USA | 0 |
NCT05115292 | Phase I | BJ-005 | A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma | Active, not recruiting | USA | 0 |
NCT05225584 | Phase I | KT-333 | Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors | Active, not recruiting | USA | 0 |
NCT05290597 | Phase I | IBI363 | A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas | Unknown status | AUS | 0 |
NCT05337735 | Phase II | XmAb20717 | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers | Suspended | USA | 0 |
NCT05463263 | Phase Ib/II | STP938 | A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas | Recruiting | USA | GBR | FRA | 0 |
NCT05544968 | Phase Ib/II | CD30biAb-AATC | CD30biAb-AATC for CD30+ Malignancies | Not yet recruiting | USA | 0 |
NCT05627245 | Phase I | Belinostat + Tazemetostat | Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment | Recruiting | USA | 0 |
NCT05698888 | Phase I | VP301 | Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors | Terminated | USA | 0 |
NCT05705570 | Phase I | Cyclophosphamide + Fludarabine MB-CART19.1 | A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies (CARTHIAE-1) | Not yet recruiting | BRA | 0 |
NCT05751798 | Phase Ib/II | OSE-279 | Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas | Recruiting | FRA | BEL | 0 |
NCT05775406 | Phase I | KT-253 | Safety and Clinical Activity of KT-253 in Adult Patients With High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors | Active, not recruiting | USA | 0 |
NCT05807035 | Phase I | Radvax | Autologous Tumour Vaccine Trial | Recruiting | AUS | 0 |
NCT05878691 | Phase I | GRC 54276 + Pembrolizumab Atezolizumab + GRC 54276 GRC 54276 | A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas. | Active, not recruiting | USA | 1 |
NCT06022029 | Phase I | ONM-501 Cemiplimab + ONM-501 | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. (ON-5001) | Recruiting | USA | AUS | 0 |
NCT06092580 | Phase I | AWT020 | Phase 1 Study of AWT020 in Advanced Cancer | Recruiting | AUS | 0 |
NCT06208657 | Phase Ib/II | GDC-0084 + Irinotecan + Temozolomide Pimasertib | Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer | Recruiting | CAN | AUS | 0 |
NCT06223542 | Phase I | TAK-243 | Studying TAK-243 in Patients With Advanced Cancer | Recruiting | USA | 0 |
NCT06326463 | Phase I | CD70-CAR-T cells Cyclophosphamide + Fludarabine Mesna | CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies | Recruiting | USA | 0 |
NCT06345027 | Phase I | CD70-CAR-T cells | CHIMERIC ANTIGEN RECEPTOR TREATMENT TARGETING CD70 (SEVENTY) (CASEY) | Not yet recruiting | USA | 0 |